Evidence map›Paper›PMID 38089573›Full record

ArticleiScience2023

MYB exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostate cancer.

Mohammad Aslam Khan, Srijan Acharya, Shashi Anand, Fnu Sameeta, Paramahansa Pramanik, Christopher Keel, Seema Singh, James Elliot Carter, Santanu Dasgupta, Ajay Pratap Singh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mohammad Aslam KhanDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL 36617, USA.
Srijan AcharyaDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL 36617, USA.
Shashi AnandDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL 36617, USA.
Fnu SameetaDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL 36617, USA.
Paramahansa PramanikDepartment of Mathematics and Statistics, University of South Alabama, Mobile, AL 36688, USA.
Christopher KeelDepartment of Urology, Frederick P. Whiddon College of Medicine, University of South Alabama, Mobile, AL 36688, USA.
Seema SinghDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL 36617, USA.
James Elliot CarterDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL 36617, USA.
Santanu DasguptaDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL 36617, USA.
Ajay Pratap SinghDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, AL 36617, USA.
USA Mitchell Cancer Institute · USUniversity of South Alabama · US

Funding

A novel molecular cross-talk driving pancreatic cancer progressionR01CA224306 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2018 to 2022
$1.7M
Molecular determinant of racial disparity in prostate cancerU01CA185490 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2014 to 2018
$1.7M
NCI NIH HHS R01 CA224306NCI NIH HHS U01 CA185490
6 · The paper itself

Abstract

MYB acts as a potentiator of aggressiveness and castration resistance in prostate cancer (PCa) through aberrant activation of androgen receptor (AR) signaling. Since Black men experience higher PCa incidence and mortality than White men, we examined if MYB was differentially expressed in prostate tumors from patients of these racial backgrounds. The data reveal that aberrant MYB expression starts early in precancerous high-grade prostate intraepithelial neoplastic lesions and increases progressively in malignant cells. PCa tissues from Black patients exhibit higher MYB expression than White patients in overall and grade-wise comparisons. MYB also exhibits a positive correlation with AR expression and both display higher expression in advanced tumor stages. Notably, we find that MYB is a better predictor of biochemical recurrence than AR, pre-treatment PSA, or Gleason's grades. These findings establish MYB as a promising molecular target in PCa that could be used for improved risk prediction and therapeutic planning.

Indexed as

CancerHealth disparityMolecular biology

Identifiers

PMID38089573
PMCPMC10711386
OpenAlexW4388802350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.